These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 24516518)

  • 21. Prevalence of ERG expression and PTEN loss in a Brazilian prostate cancer cohort.
    Morais CE; Gurgel DC; Teixeira AC; Mattos TVA; Silva AVAD; Tavora F
    Braz J Med Biol Res; 2019; 52(12):e8483. PubMed ID: 31826177
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The prognostic impact of high Nijmegen breakage syndrome (NBS1) gene expression in ERG-negative prostate cancers lacking PTEN deletion is driven by KPNA2 expression.
    Grupp K; Boumesli R; Tsourlakis MC; Koop C; Wilczak W; Adam M; Sauter G; Simon R; Izbicki JR; Graefen M; Huland H; Steurer S; Schlomm T; Minner S; Quaas A
    Int J Cancer; 2014 Sep; 135(6):1399-407. PubMed ID: 24510842
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Heterogeneity and chronology of PTEN deletion and ERG fusion in prostate cancer.
    Krohn A; Freudenthaler F; Harasimowicz S; Kluth M; Fuchs S; Burkhardt L; Stahl P; C Tsourlakis M; Bauer M; Tennstedt P; Graefen M; Steurer S; Sirma H; Sauter G; Schlomm T; Simon R; Minner S
    Mod Pathol; 2014 Dec; 27(12):1612-20. PubMed ID: 24762546
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer.
    Krohn A; Diedler T; Burkhardt L; Mayer PS; De Silva C; Meyer-Kornblum M; Kötschau D; Tennstedt P; Huang J; Gerhäuser C; Mader M; Kurtz S; Sirma H; Saad F; Steuber T; Graefen M; Plass C; Sauter G; Simon R; Minner S; Schlomm T
    Am J Pathol; 2012 Aug; 181(2):401-12. PubMed ID: 22705054
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aquaporin 5 expression is frequent in prostate cancer and shows a dichotomous correlation with tumor phenotype and PSA recurrence.
    Pust A; Kylies D; Hube-Magg C; Kluth M; Minner S; Koop C; Grob T; Graefen M; Salomon G; Tsourlakis MC; Izbicki J; Wittmer C; Huland H; Simon R; Wilczak W; Sauter G; Steurer S; Krech T; Schlomm T; Melling N
    Hum Pathol; 2016 Feb; 48():102-10. PubMed ID: 26614400
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TMPRSS2-ERG gene fusion is rare compared to PTEN deletions in stage T1a prostate cancer.
    Fisher KW; Zhang S; Wang M; Montironi R; Wang L; Baldrige LA; Wang JY; MacLennan GT; Williamson SR; Lopez-Beltran A; Cheng L
    Mol Carcinog; 2017 Mar; 56(3):814-820. PubMed ID: 27500376
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular alterations of EGFR and PTEN in prostate cancer: association with high-grade and advanced-stage carcinomas.
    de Muga S; Hernández S; Agell L; Salido M; Juanpere N; Lorenzo M; Lorente JA; Serrano S; Lloreta J
    Mod Pathol; 2010 May; 23(5):703-12. PubMed ID: 20208477
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Loss of PTEN is associated with aggressive behavior in ERG-positive prostate cancer.
    Leinonen KA; Saramäki OR; Furusato B; Kimura T; Takahashi H; Egawa S; Suzuki H; Keiger K; Ho Hahm S; Isaacs WB; Tolonen TT; Stenman UH; Tammela TL; Nykter M; Bova GS; Visakorpi T
    Cancer Epidemiol Biomarkers Prev; 2013 Dec; 22(12):2333-44. PubMed ID: 24083995
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The impact of PTEN deletion and ERG rearrangement on recurrence after treatment for prostate cancer: a systematic review and meta-analysis.
    Liu R; Zhou J; Xia S; Li T
    Clin Transl Oncol; 2020 May; 22(5):694-702. PubMed ID: 31359337
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel, gross chromosomal alterations involving PTEN cooperate with allelic loss in prostate cancer.
    Reid AH; Attard G; Brewer D; Miranda S; Riisnaes R; Clark J; Hylands L; Merson S; Vergis R; Jameson C; Høyer S; Sørenson KD; Borre M; Jones C; de Bono JS; Cooper CS
    Mod Pathol; 2012 Jun; 25(6):902-10. PubMed ID: 22460813
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A multicenter study shows PTEN deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer.
    Troyer DA; Jamaspishvili T; Wei W; Feng Z; Good J; Hawley S; Fazli L; McKenney JK; Simko J; Hurtado-Coll A; Carroll PR; Gleave M; Lance R; Lin DW; Nelson PS; Thompson IM; True LD; Brooks JD; Squire JA
    Prostate; 2015 Aug; 75(11):1206-15. PubMed ID: 25939393
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Integrated analysis of the genomic instability of PTEN in clinically insignificant and significant prostate cancer.
    Murphy SJ; Karnes RJ; Kosari F; Castellar BE; Kipp BR; Johnson SH; Terra S; Harris FR; Halling GC; Klein JL; Nasir A; Bergstrahl E; Rangel LJ; Sukov WR; Vasmatzis G; Cheville JC
    Mod Pathol; 2016 Feb; 29(2):143-56. PubMed ID: 26612463
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence and Prognostic Significance of PTEN Loss in African-American and European-American Men Undergoing Radical Prostatectomy.
    Tosoian JJ; Almutairi F; Morais CL; Glavaris S; Hicks J; Sundi D; Humphreys E; Han M; De Marzo AM; Ross AE; Tomlins SA; Schaeffer EM; Trock BJ; Lotan TL
    Eur Urol; 2017 May; 71(5):697-700. PubMed ID: 27477529
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular evidence that invasive adenocarcinoma can mimic prostatic intraepithelial neoplasia (PIN) and intraductal carcinoma through retrograde glandular colonization.
    Haffner MC; Weier C; Xu MM; Vaghasia A; Gürel B; Gümüşkaya B; Esopi DM; Fedor H; Tan HL; Kulac I; Hicks J; Isaacs WB; Lotan TL; Nelson WG; Yegnasubramanian S; De Marzo AM
    J Pathol; 2016 Jan; 238(1):31-41. PubMed ID: 26331372
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High RNA-binding motif protein 3 expression is an independent prognostic marker in operated prostate cancer and tightly linked to ERG activation and PTEN deletions.
    Grupp K; Wilking J; Prien K; Hube-Magg C; Sirma H; Simon R; Steurer S; Budäus L; Haese A; Izbicki J; Sauter G; Minner S; Schlomm T; Tsourlakis MC
    Eur J Cancer; 2014 Mar; 50(4):852-61. PubMed ID: 24380696
    [TBL] [Abstract][Full Text] [Related]  

  • 36. FLI1 is a novel ETS transcription factor involved in gene fusions in prostate cancer.
    Paulo P; Barros-Silva JD; Ribeiro FR; Ramalho-Carvalho J; Jerónimo C; Henrique R; Lind GE; Skotheim RI; Lothe RA; Teixeira MR
    Genes Chromosomes Cancer; 2012 Mar; 51(3):240-9. PubMed ID: 22081504
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relevance of cohort design for studying the frequency of the ERG rearrangement in prostate cancer.
    Braun M; Scheble VJ; Menon R; Scharf G; Wilbertz T; Petersen K; Beschorner C; Reischl M; Kuefer R; Schilling D; Stenzl A; Kristiansen G; Rubin MA; Fend F; Perner S
    Histopathology; 2011 Jun; 58(7):1028-36. PubMed ID: 21707704
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Overexpression of ERG and Wild-Type PTEN Are Associated with Favorable Clinical Prognosis and Low Biochemical Recurrence in Prostate Cancer.
    Kim SH; Kim SH; Joung JY; Lee GK; Hong EK; Kang KM; Yu A; Nam BH; Chung J; Seo HK; Park WS; Lee KH
    PLoS One; 2015; 10(4):e0122498. PubMed ID: 25897494
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of DNA ligase IV is linked to poor prognosis and characterizes a subset of prostate cancers harboring TMPRSS2:ERG fusion and PTEN deletion.
    Grupp K; Roettger L; Kluth M; Hube-Magg C; Simon R; Lebok P; Minner S; Tsourlakis MC; Koop C; Graefen M; Adam M; Haese A; Wittmer C; Sauter G; Wilczak W; Huland H; Schlomm T; Steurer S; Krech T
    Oncol Rep; 2015 Sep; 34(3):1211-20. PubMed ID: 26134445
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reduced AZGP1 expression is an independent predictor of early PSA recurrence and associated with ERG-fusion positive and PTEN deleted prostate cancers.
    Burdelski C; Kleinhans S; Kluth M; Hube-Magg C; Minner S; Koop C; Graefen M; Heinzer H; Tsourlakis MC; Wilczak W; Marx A; Sauter G; Wittmer C; Huland H; Simon R; Schlomm T; Steurer S
    Int J Cancer; 2016 Mar; 138(5):1199-206. PubMed ID: 26383228
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.